光动力疗法
材料科学
光敏剂
纳米技术
白蛋白
光化学
生物医学工程
医学
生物化学
有机化学
化学
作者
Hao Ren,Jiaqi Liu,Fenhong Su,Sizhan Ge,Ahu Yuan,Weimin Dai,Jinhui Wu,Yiqiao Hu
标识
DOI:10.1021/acsami.6b14885
摘要
Photodynamic therapy (PDT) is hampered by poor water solubility and skin phototoxicity of photosensitizers (PSs). Incorporation of PSs into nanocarrier (Nano-PDT) has been designed to overcome these problems. However, self-quenching of PSs highly condensed in Nano-PDT significantly reduced singlet oxygen ( 1 O 2 ) generation, resulting in unsatisfactory PDT efficacy. Here, we developed a novel tripleffect Nano-PDT, which has a special core–shell nanostructure by synergistic integration of perfluorotributylamine (PFTBA) and human serum albumin (HSA) to improve PDT. It has three mechanisms to relight quenched PSs, thereby generating more 1 O 2 . First, PSs uniformly dispersed in the shell, preventing self-quenching caused by π–π stacking. Second, HSA as nanocarrier extends the triplet-state lifetimes of PSs, increasing the amount of 1 O 2 . Third, PFTBA as core dissolves and protects 1 O 2 to extend the duration time of action of 1 O 2 . Compared with PS-encapsulated Nano-PDT, the self-quenching of PSs in tripleffect Nano-PDT can be effectively overcome. The fluorescence and 1 O 2 generation of PS are increased by approximately 100-fold and 15-fold, respectively. After intravenous injection into tumor-bearing mice, the tumor growth is significantly inhibited, while the PS-encapsulated Nano-PDT has almost no effect. The novel tripleffect Nano-PDT may guide improvement of existing clinical PDT and future PDT design.
科研通智能强力驱动
Strongly Powered by AbleSci AI